Kunte Sophie C, Wenter Vera, Toms Johannes, Lindner Simon, Unterrainer Marcus, Eilsberger Friederike, Jurkschat Klaus, Wängler Carmen, Wängler Björn, Schirrmacher Ralf, Tiling Maximilian W, Sheikh Gabriel T, Mehrens Dirk, Brendel Matthias, Rübenthaler Johannes, Auernhammer Christoph J, Spitzweg Christine, Unterrainer Lena M, Holzgreve Adrien
Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
DIE RADIOLOGIE, Munich, Germany.
Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):900-912. doi: 10.1007/s00259-024-06944-y. Epub 2024 Oct 15.
The novel F-labeled somatostatin receptor (SSTR)-directed radiotracer [F]SiTATE demonstrated promising results for the imaging of various SSTR-expressing tumor types. Although thyroid carcinomas (TC) express SSTR, data on [F]SiTATE PET/CT imaging in TC are lacking. This study explores the use of [F]SiTATE PET/CT in a patient cohort with histologically proven TC.
As part of a prospective observational study at a single tertiary cancer center, 21 patients with TC (10 medullary (MTC) and 11 differentiated (DTC)) who underwent at least one [F]SiTATE PET/CT were included (37 scans in total). Mean SUV and SUV of tumoral lesions, mean total-tumor-volume (TTV), and whole-body (WB)-SUV and WB-SUV on PET with their standard deviations (SDs) were determined. PET parameters were correlated to clinical parameters including tumor marker levels (thyroglobulin for DTC, calcitonin for MTC).
89 lesions were included in the analysis. Metastases were localized in the bone, lymph nodes, lung, soft tissue, and thyroid bed. Osseous (31 lesions; SUV 8.6 ± 8.0; SUV 5.8 ± 5.4) and nodal (37 lesions; SUV 8.7 ± 7.8; SUV 5.7 ± 5.4) metastases showed the highest uptake. The MTC disease burden on PET significantly correlated with the calcitonin tumor marker level (e.g., TTV: r = 0.771, r = 0.594, p = 0.002). For DTC, no such correlation was present.
Our data demonstrate high feasibility of [F]SiTATE PET/CT in a small cohort of patients with MTC and DTC. The use of [F]SiTATE may overcome logistical disadvantages of Ga-based tracers and facilitate SSTR-targeted PET/CT imaging of thyroid carcinoma.
新型F标记的生长抑素受体（SSTR）导向放射性示踪剂[F]SiTATE在多种表达SSTR的肿瘤类型成像方面显示出有前景的结果。尽管甲状腺癌（TC）表达SSTR，但缺乏关于[F]SiTATE PET/CT在TC中成像的数据。本研究探讨[F]SiTATE PET/CT在一组经组织学证实为TC的患者中的应用。
作为在一家单一的三级癌症中心进行的前瞻性观察性研究的一部分，纳入了21例接受至少一次[F]SiTATE PET/CT检查的TC患者（10例髓样癌（MTC）和11例分化型癌（DTC））（共37次扫描）。确定肿瘤病变的平均SUV和SUV、平均总肿瘤体积（TTV）以及PET上的全身（WB）-SUV和WB-SUV及其标准差（SD）。PET参数与包括肿瘤标志物水平（DTC为甲状腺球蛋白，MTC为降钙素）在内的临床参数相关。
分析纳入89个病变。转移灶定位于骨、淋巴结、肺、软组织和甲状腺床。骨转移（31个病变；SUV 8.6±8.0；SUV 5.8±5.4）和淋巴结转移（37个病变；SUV 8.7±7.8；SUV 5.7±5.4）摄取最高。PET上MTC的疾病负担与降钙素肿瘤标志物水平显著相关（例如，TTV：r = 0.771，r = 0.594，p = 0.002）。对于DTC，不存在这种相关性。
我们的数据表明[F]SiTATE PET/CT在一小群MTC和DTC患者中具有高度可行性。[F]SiTATE的使用可能克服基于镓的示踪剂的后勤劣势，并促进甲状腺癌的SSTR靶向PET/CT成像。
